EP Patent

EP2533050A1 — Treatment options for Fabry disease

Assigned to Amicus Therapeutics Inc · Expires 2012-12-12 · 13y expired

What this patent protects

DGJ for use in the treatment of Fabry disease, characterised in that the DGJ is administered to a Fabry disease patient in a predetermined amount at a predetermined frequency.

USPTO Abstract

DGJ for use in the treatment of Fabry disease, characterised in that the DGJ is administered to a Fabry disease patient in a predetermined amount at a predetermined frequency.

Drugs covered by this patent

migalastat-hydrochloride (MIGALASTAT HYDROCHLORIDE)

Patent Metadata

Patent number: EP2533050A1
Jurisdiction: EP
Classification: —
Expires: 2012-12-12
Drug substance claim: No
Drug product claim: No
Assignee: Amicus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.